--- title: "DXCM DexCom" canonical: "https://supercyclehq.com/stock/dexcom" type: "stock" dataAsOf: "2026-11-06" ticker: "DXCM" license: "Free to use and quote with attribution to supercyclehq.com. Do not redistribute as a dataset." disclaimer: "Informational only, not investment advice. The AI Exposure Score is Supercycle's editorial opinion. Agent portfolios are simulated paper portfolios run by AI." --- # DexCom (DXCM) DexCom makes continuous glucose monitors, wearable sensors that track blood sugar in real time for people with diabetes. ## AI Exposure Score **8/100, Peripheral.** DexCom sells continuous glucose monitors, with AI algorithms for glucose prediction and dosing insights. Revenue depends on sensor adoption and reimbursement, so AI is a product feature with peripheral buildout exposure. ## Quote | Field | Value | | --- | --- | | Price (EOD close) | $79.41 | | Change 1d | -5.98% | | Change 7d | -3.50% | | Change 30d | -5.92% | | Change 1y | +44.38% | | 52-week high | $92.34 | | 52-week low | $54.84 | | Market cap | $29.6B | | P/E | 31.26 | | EPS | $2.54 | | Next earnings | 2026-10-29 | Quote as of 2026-11-06. ## Company | Field | Value | | --- | --- | | Exchange | NASDAQ | | Sector | Healthcare | | Headquarters | San Diego, California | | CEO | Jacob Steven Leach | | Employees | 11,000 | | Website | https://www.dexcom.com | | Buildout layers | [AI Healthcare](https://supercyclehq.com/category/ai-healthcare) | ## What the company does DexCom makes continuous glucose monitors, wearable sensors that track blood sugar in real time for people with diabetes. It earns revenue from sensor sales, driven by patient adoption and insurance reimbursement, and its devices pair with apps that turn readings into guidance. AI shapes that guidance layer. Its glucose prediction algorithms warn users where their levels are heading, Stelo AI Analytics adds the same intelligence to its Stelo product line, Clarity AI Reports summarize patterns for patients and doctors, and smart insulin dosing AI helps inform dosing decisions. Founded in 1999 and headquartered in San Diego, California, DexCom trades on the NASDAQ and employs roughly 11,000 people. ## Role in the AI buildout DexCom sits at the periphery of the AI Healthcare layer of the buildout. AI algorithms make its glucose data more useful, powering prediction, pattern recognition, and dosing insights. But the business runs on sensor adoption and reimbursement decisions, not AI demand, so AI is a product feature rather than a growth driver. Supercycle assigns it an AI Exposure Score of 8 out of 100. ## Tracked investors holding it (13F) | Investor | Fund | Position value | Portfolio % | Change | Period | | --- | --- | --- | --- | --- | --- | | [George Soros](https://supercyclehq.com/investors/george-soros) | Soros Fund Management | $63.5M | 0.83% | increased | 2026-06-30 | | [Ray Dalio](https://supercyclehq.com/investors/ray-dalio) | Bridgewater Associates | $27.0M | 0.11% | increased | 2026-06-30 | ## Recent news - [Guardant Health (GH) Could Be 17% Undervalued As Board Appointment Tests Valuation](https://finance.yahoo.com/markets/stocks/articles/guardant-health-gh-could-17-051903253.html?.tsrc=rss) (source, 2026-11-05) - [DexCom to Launch 15-Day G7 CGM System in Canada This November](https://finance.yahoo.com/healthcare/articles/dexcom-launch-15-day-g7-155900537.html?.tsrc=rss) (source, 2026-11-03) - [Biosensors - Global Strategic Business Report: Secure Share of the $53.7 Billion Market by 2030 as Abbott, Dexcom, Medtronic and Masimo Accelerate Wearable and AI Diagnostics](https://finance.yahoo.com/healthcare/articles/biosensors-global-strategic-business-report-144100028.html?.tsrc=rss) (source, 2026-11-03) - [Abbott, Dexcom grapple with diabetes coverage ahead of planned Medicare expansion](https://www.medtechdive.com/news/abbott-dexcom-grapple-with-diabetes-coverage-ahead-of-planned-medicare-exp/873461/?.tsrc=rss) (source, 2026-11-02) - [Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign](https://finance.yahoo.com/healthcare/articles/dexcom-invites-global-diabetes-community-130000363.html?.tsrc=rss) (source, 2026-11-02) ## FAQ ### What does DexCom do? DexCom makes continuous glucose monitors, wearable sensors that track blood sugar in real time for people managing diabetes. Revenue comes from sensor sales supported by insurance reimbursement. ### How is DexCom exposed to AI? AI powers glucose prediction, pattern recognition, and dosing insights in its apps, but revenue depends on sensor adoption and reimbursement. Supercycle rates it an AI Exposure Score of 8 out of 100. ### What are DexCom's main AI products? Dexcom AI Glucose Prediction for forecasting blood sugar trends, Stelo AI Analytics, Clarity AI Reports for summarizing patterns, and smart insulin dosing AI that helps inform dosing decisions. ### Is DXCM a pure play AI stock? No. DexCom is a medical device company where AI enhances the product experience. Its AI Exposure Score of 8 out of 100 places it near the low end of Supercycle's rankings. ### Where is DexCom based and who leads it? DexCom is headquartered in San Diego, California, and is led by CEO Jacob Steven Leach. Founded in 1999, it employs roughly 11,000 people and trades on the NASDAQ. --- Source: https://supercyclehq.com/stock/dexcom. Data as of 2026-11-06. Prices are end-of-day closes, never live. Informational only, not investment advice. The AI Exposure Score is Supercycle's editorial opinion. Agent portfolios are simulated paper portfolios run by AI. Free to use and quote with attribution to supercyclehq.com. Do not redistribute as a dataset.